New Article Directory Alaska: July 2011

Monday, 25 July 2011

Tiapaston

Tiapaston may be available in the countries listed below.

Ingredient matches for Tiapaston

Tiquizium Bromide

Tiquizium Bromide is reported as an ingredient of Tiapaston in the following countries:

Japan

International Drug Name Search

Doprovet

Doprovet may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Doprovet

Doxycycline

Doxycycline monohydrate (a derivative of Doxycycline) is reported as an ingredient of Doprovet in the following countries:

Italy

International Drug Name Search

Friday, 22 July 2011

Tozolden

Tozolden may be available in the countries listed below.

Ingredient matches for Tozolden

Atenolol

Atenolol is reported as an ingredient of Tozolden in the following countries:

Argentina

International Drug Name Search

Friday, 15 July 2011

Beta Ointment

Beta Ointment may be available in the countries listed below.

Ingredient matches for Beta Ointment

Betamethasone

Betamethasone 17α-valerate (a derivative of Betamethasone) is reported as an ingredient of Beta Ointment in the following countries:

New Zealand

International Drug Name Search

Thursday, 14 July 2011

Cystichol

Cystichol may be available in the countries listed below.

Ingredient matches for Cystichol

Choline

Choline hydrogentartrate (a derivative of Choline) is reported as an ingredient of Cystichol in the following countries:

France

Cystine

Cystine is reported as an ingredient of Cystichol in the following countries:

France

International Drug Name Search

Tuesday, 12 July 2011

Oxytocin Bengen

Oxytocin Bengen may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Oxytocin Bengen

Oxytocin

Oxytocin is reported as an ingredient of Oxytocin Bengen in the following countries:

Germany

International Drug Name Search

Monday, 11 July 2011

Genta-Sulfat

Genta-Sulfat may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Genta-Sulfat

Gentamicin

Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Genta-Sulfat in the following countries:

Germany

International Drug Name Search

Novo-Gesic

Novo-Gesic may be available in the countries listed below.

Ingredient matches for Novo-Gesic

Paracetamol

Paracetamol is reported as an ingredient of Novo-Gesic in the following countries:

Poland

International Drug Name Search

Saturday, 9 July 2011

DesOwen Cream

Pronunciation: DES-oh-nide
Generic Name: Desonide
Brand Name: Examples include DesOwen and Tridesilon

DesOwen Cream is used for:

Treating mild to moderate itching, redness, and swelling caused by certain skin conditions.

DesOwen Cream is a topical corticosteroid. It works by reducing skin inflammation (redness, swelling, itching, and irritation).

Do NOT use DesOwen Cream if:

you are allergic to any ingredient in DesOwen Cream

Contact your doctor or health care provider right away if any of these apply to you.

Before using DesOwen Cream:

Some medical conditions may interact with DesOwen Cream. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have any kind of skin infection, cuts, scrapes, or lessened blood flow to your skin

if you have measles, tuberculosis (TB), chickenpox, shingles, or a positive TB skin test, or if you have recently had a vaccination

if you are taking an oral corticosteroid (eg, prednisone)

Some MEDICINES MAY INTERACT with DesOwen Cream. Because little, if any, of DesOwen Cream is absorbed into the blood, the risk of it interacting with another medicine is low.

Ask your health care provider if DesOwen Cream may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use DesOwen Cream:

Use DesOwen Cream as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Apply a thin film of DesOwen Cream to the affected area(s) as directed by your doctor. Gently rub the medicine in until it is evenly distributed.

Wash your hands immediately after applying DesOwen Cream, unless your hands are part of the treated area.

Do not cover the treated area(s) with bandages or other dressings unless advised to do so by your health care provider.

If you miss a dose of DesOwen Cream, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use DesOwen Cream.

Important safety information:

DesOwen Cream is for external use only. Do not get it in your eyes, nose, or mouth. If you get it in any of these areas, flush right away with cool tap water.

Do NOT use more than the recommended dose or use for longer than prescribed without checking with your doctor.

Talk with your doctor before you use any other medicines or cleansers on your skin.

Do not apply DesOwen Cream over large areas of the body, to open wounds, or to scraped, infected, or burned skin without first checking with your doctor.

Do not use DesOwen Cream for other skin conditions at a later time.

Overuse of topical products may worsen your condition.

If DesOwen Cream was prescribed to treat the diaper area of a child, avoid using tight-fitting diapers or plastic pants.

Check with your doctor before you receive any vaccine while you are using DesOwen Cream.

DesOwen Cream has a corticosteroid in it. Before you start any new medicine, check the label to see if it has a corticosteroid in it too. If it does or you are not sure, check with your doctor or pharmacist.

Tell your doctor or dentist that you take DesOwen Cream before you receive any medical or dental care, emergency care, or surgery.

Contact your doctor if you have a cut or sore that does not heal.

Serious side effects may occur if too much of DesOwen Cream is absorbed through the skin. This may be more likely to occur if you use DesOwen Cream over a larger area of the body. It may also be more likely if you wrap or bandage the area after you apply DesOwen Cream. The risk is greater in children. Do not use more than the prescribed dose. Contact your doctor right away if you develop unusual weight gain (especially in the face), muscle weakness, increased thirst or urination, confusion, unusual drowsiness, severe or persistent headache, or vision changes. Discuss any questions or concerns with your doctor.

Corticosteroids may affect growth rate in CHILDREN and teenagers in some cases. They may need regular growth checks while they use DesOwen Cream.

PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using DesOwen Cream while you are pregnant. It is not known if DesOwen Cream is found in breast milk after topical use. If you are or will be breast-feeding while you use DesOwen Cream, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of DesOwen Cream:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Mild, temporary stinging or burning when first applied.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); acne-like rash; inflamed hair follicles; inflammation around the mouth; severe or persistent burning, irritation, redness, or swelling of the skin; thinning, softening, or discoloration of the skin.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: DesOwen side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision or other vision changes; muscle weakness; severe or persistent headache; symptoms of high blood sugar (eg, increased thirst or urination, confusion, unusual drowsiness); unusual weight gain, especially in the face.

Proper storage of DesOwen Cream:

Store DesOwen Cream at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store in a tightly closed container. Do not freeze. Store away from heat, moisture, and light. Do not store in the bathroom. Keep DesOwen Cream out of the reach of children and away from pets.

General information:

If you have any questions about DesOwen Cream, please talk with your doctor, pharmacist, or other health care provider.

DesOwen Cream is to be used only by the patient for whom it is prescribed. Do not share it with other people.

If your symptoms do not improve or if they become worse, check with your doctor.

Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about DesOwen Cream. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

More DesOwen resources

DesOwen Side Effects (in more detail)
DesOwen Use in Pregnancy & Breastfeeding
DesOwen Drug Interactions
DesOwen Support Group
5 Reviews for DesOwen - Add your own review/rating

Compare DesOwen with other medications

Atopic Dermatitis
Dermatitis
Eczema
Psoriasis

Tuesday, 5 July 2011

Non-Small Cell Lung Cancer Medications

Drugs associated with Non-Small Cell Lung Cancer

The following drugs and medications are in some way related to, or used in the treatment of Non-Small Cell Lung Cancer. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Learn more about Non-Small Cell Lung Cancer

Micromedex Care Notes:

Lung Cancer

Harvard Health Guide:

Symptoms and treatment for Non-Small Cell Lung Cancer

Drug List:

Alimta

Avastin

Cytoxan

Cytoxan-Lyophilized-Oral-Injection

Saturday, 2 July 2011

Oxandrolone

Class: Androgens
ATC Class: A14AA
VA Class: HS100
Chemical Name: 17β-Hydroxy-17-αmethyl-2-oxa-5α-androstan-3-one
Molecular Formula: C₁₉H₃₀O₃
CAS Number: 53-39-4
Brands: Oxandrin

Peliosis Hepatis

Peliosis hepatis, a condition in which the liver contains blood-filled cysts, reported with androgen therapy.¹ ⁴ ³⁰ ³¹ ³⁴ May present with minimal hepatic dysfunction,¹ ⁴ ³⁴ or effects may not be apparent until complicated by life-threatening liver failure or rupture of the cysts resulting in intra-abdominal hemorrhage.¹ ⁴ ⁵ ⁷ ³¹ ³⁴ (See Hepatic Effects under Cautions.)

Discontinuance of androgen therapy usually results in resolution of liver lesions.¹ ⁴ ³² ³⁴

Hepatic Adenoma and Carcinoma

Liver cell tumors reported with androgen therapy.¹ ⁴ ⁵ ⁷ ³⁰ ³¹ ³⁴ Tumors are usually benign and androgen dependent; hepatocellular carcinoma, sometimes fatal, also reported.¹ ⁴ ⁵ ⁷ ³⁴

Liver cell tumors associated with androgens are more vascular than other hepatic tumors; hepatic effects may not be apparent until complicated by life-threatening intra-abdominal hemorrhage.¹ ⁴ ⁵ ³⁴

Discontinuance of androgen therapy often but not always results in regression or cessation of progression of the tumor.¹ ⁴ ⁵ ³⁴

Lipid Abnormalities

May markedly alter serum lipoprotein concentrations; decreased HDL- and increased LDL-cholesterol reported with androgen therapy.¹ ⁴ ³⁰ ³¹ ³⁴ Consider increased risk of cardiovascular disease (e.g., atherosclerosis and CAD).¹ ⁴ ³¹ ³⁴ (See Lipid Abnormalities under Cautions.)

Introduction

Synthetic androgenic anabolic steroid hormone.¹ ⁴

Uses for Oxandrolone

Catabolic and Wasting Disorders

Adjunct to conventional therapy to promote weight gain in individuals who experience weight loss following extensive surgery, chronic infections (e.g., HIV-associated wasting syndrome; designated an orphan drug by FDA for this use),³ or severe trauma (e.g., burns, spinal cord injury).¹ ⁵ ¹⁷ ¹⁹ ²² ³²

Adjunct to conventional therapy for management of unexplained weight loss.¹

Corticosteroid-induced Protein Catabolism

Adjunct to conventional therapy to offset protein catabolism (e.g., muscle wasting, muscle pain or weakness, delayed wound healing, atrophy of protein matrix of bone) associated with long-term corticosteroid therapy.¹ ⁴ ²⁰ ²¹ ³³

Osteoporosis

Labeled for the symptomatic treatment of bone pain accompanying osteoporosis.¹ ⁴ ²³

Misuse and Abuse

Androgens have been misused and abused by athletes, bodybuilders, weight lifters, and others to enhance athletic performance or physique†.⁶ ⁷ ⁸ ⁹ ¹⁰ ³²

Medical and sports experts (e.g., International Olympic Committee) consider such use to be inappropriate and unacceptable because of known adverse effects and potential long-term sequelae.⁹ Such misuse by athletes is contrary to rules and ethical principles of athletic competition.⁷ ⁸ ⁹ ¹⁰

Manufacturer states that androgens have not been shown to enhance athletic performance.¹

Oxandrolone Dosage and Administration

General

Individualize dosage and duration of therapy carefully according to individual requirements, response, and tolerance.¹ ⁴ Use the minimum effective dosage; intended for intermittent use.¹ ⁴ ²²

Administration

Oral Administration

Administer orally 2–4 times daily in adults.¹ ⁴

Dosage

Pediatric Patients

Catabolic and Wasting Disorders

Oral

≤0.1 mg/kg daily for 2–4 weeks.¹ ⁴ Repeat course of therapy intermittently as needed to maintain weight.¹ ⁴ ³²

Higher than recommended dosage of 0.1 mg/kg twice daily for 5 days to 12 months† has been evaluated in pediatric patients with burns.¹ ⁴ ⁵ ¹⁶ ¹⁷ ¹⁸ ³²

Corticosteroid-induced Protein Catabolism

Oral

≤0.1 mg/kg daily.¹ ⁴ Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response.¹ ⁴ ³² Repeat course of therapy intermittently as needed.¹ ⁴ ³²

Adults

Catabolic and Wasting Disorders

Oral

2.5–20 mg daily in 2–4 divided doses for 2–4 weeks.¹ ⁴ Repeat course of therapy intermittently as needed to maintain weight.¹ ⁴ ³²

Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response (i.e., slowing or cessation of weight loss).¹ ⁴ ³² A longer period of treatment is necessary to regain lost weight, especially if ongoing catabolic stressors are present.³² Continuous administration for 3–4 months has been evaluated in patients with HIV-associated wasting syndrome.⁵ ¹⁹

Corticosteroid-induced Protein Catabolism

Oral

2.5–20 mg daily in 2–4 divided doses.¹ ⁴ Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response.¹ ⁴ ³² Repeat course of therapy intermittently as needed.¹ ⁴ ³²

Osteoporosis

Bone Pain

Oral

2.5–20 mg daily in 2–4 divided doses.¹ ⁴ Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response.¹ ⁴ Repeat course of therapy intermittently as needed.¹ ⁴

Special Populations

Geriatric Patients

5 mg twice daily for 2–4 weeks recommended.¹ Repeat course of therapy intermittently as needed.¹ (See Geriatric Use under Cautions.)

Cautions for Oxandrolone

Contraindications

Males with breast cancer or known or suspected prostate cancer.¹ ⁴

Women with hypercalcemia associated with metastatic breast cancer.¹ ⁴ (See Hypercalcemia under Cautions.)

Known or suspected pregnancy.¹ ⁴ (See Fetal/Neonatal Morbidity and Mortality under Cautions.)

Nephrosis.¹ ⁴

Hypercalcemia.¹ ⁴ (See Hypercalcemia under Cautions.)

Warnings/Precautions

Warnings

Fetal/Neonatal Morbidity and Mortality

May cause fetal harm; potential for virilization of fetus.¹ ⁴

Fetotoxicity, embryotoxicity, infertility, and virilization of female offspring demonstrated in animals.¹ ⁴

Hepatic Effects

Potentially serious and/or life-threatening adverse hepatic effects (e.g., peliosis hepatis, hepatic adenomas, hepatocellular carcinoma) associated with prolonged use of high dosages of androgens.⁵ ⁶ ⁷ ⁹ ¹⁰ ²² (See Boxed Warning.)

If cholestatic hepatitis with jaundice occurs, or if liver function test results become abnormal during therapy, discontinue oxandrolone and investigate etiology of these disorders.¹ ⁴ Drug-induced jaundice usually is reversible after discontinuance of drug.¹ ⁴

Monitor liver function periodically.¹ ⁴ ¹⁷ ²²

Hypercalcemia

Possible hypercalcemia resulting from osteolysis in women with metastatic carcinoma of the breast.¹ ⁴ Monitor urine and serum calcium concentrations frequently during the course of androgen therapy in women with metastatic breast cancer.¹ ⁴ ³⁰

If hypercalcemia occurs, discontinue the drug.¹ ⁴ (See Contraindications under Cautions.)

Fluid Retention

Edema, with or without CHF, possible as a result of sodium and water retention and may be a serious complication in patients with preexisting cardiac, renal, or hepatic disease.¹ ⁴ ³⁰ (See Geriatric Use under Cautions.)

Misuse and Abuse

Potential for serious adverse effects (e.g., increased aggression,⁶ ⁷ ⁸ ¹⁰ ¹³ ²² antisocial behavior,⁶ ⁷ manic episode,⁶ ²² depression,⁹ changes in libido,⁶ ⁷ ⁸ ⁹ ¹⁰ ²² increased risk of cardiovascular disease,⁶ ⁷ ⁸ ⁹ hepatotoxicity⁶ ⁷ ⁸ ⁹ ¹⁰ ) associated with misuse and abuse of androgens (see Misuse and Abuse under Uses); oxandrolone preparations currently subject to control under the Federal Controlled Substances Act of 1970, as amended by the Anabolic Steroids Control Act of 1990 and 2004, as schedule III (C-III) drugs.¹¹ ³²

General Precautions

Virilization

Virilization, including baldness, clitoral enlargement, deepening of voice, hirsutism, and menstrual irregularities, may occur in females.¹ ⁴ ⁵ ⁶ ⁹ ¹³

Monitor women receiving oxandrolone therapy for signs of virilization.¹ ⁴ If virilization occurs, promptly discontinue therapy.¹ ⁴ Some changes may not be reversible (e.g., clitoral enlargement, voice changes) after discontinuance of the drug; concomitant use of estrogen with androgens does not prevent these effects.¹ ⁴ ⁶ ⁷ ³²

Hematologic Effects

Possible polycythemia, especially with high dosages of androgens.¹ ⁴ ³⁰ Perform periodic hemoglobin and hematocrit determinations in patients receiving high dosages of androgens.¹ ⁴ ³⁰

Anabolic steroids may suppress clotting factors II, V, VII, and X and prolong PT.¹ ⁴ (See Specific Drugs and Laboratory Tests under Interactions.)

Lipid Abnormalities

Androgens may increase LDL-cholesterol and decrease HDL-cholesterol concentrations; consider the increased risk for cardiovascular disease.¹ ⁴ ⁵ ⁶ ⁷ ¹⁰ ¹² ¹³ ¹⁹ ²² ³² Lipid concentrations return to baseline values approximately 1 month after discontinuance of androgen therapy.²²

Use with caution in patients with cardiovascular disease or risk factors for cardiovascular disease.¹ ⁴ Determine serum lipid concentrations periodically; adjust therapy accordingly.¹ ⁴

Specific Populations

Pregnancy

Category X.¹ ⁴ (See Fetal/Neonatal Morbidity and Mortality and also Contraindications under Cautions.)

Lactation

Not known whether oxandrolone is distributed into milk.¹ ⁴ Discontinue nursing or the drug.¹ ⁴

Pediatric Use

May accelerate bone maturation without producing compensatory gain in linear growth, possibly resulting in compromised adult stature.¹ ⁴ ¹⁰ The younger the child, the greater the risk of the drug compromising final mature stature.¹ ⁴

Use with extreme caution in children and only under the supervision of a specialist who is aware of the adverse effects of oxandrolone on bone maturation.¹ ⁴ Perform radiographic examination of the left hand and wrist every 6 months to determine rate of bone maturation and to assess the effect of treatment on epiphyseal centers.¹ ⁴

Geriatric Use

Possible increased risk of developing prostatic hypertrophy and prostate cancer during androgen therapy.¹ ⁴ ³⁰

Response in patients ≥65 years of age does not appear to differ from that in younger adults.¹ Increased sensitivity to fluid retention and increases in hepatic transaminase values reported, particularly in geriatric women.¹ Use lower dosage to minimize adverse effects.¹ (See Geriatric Patients under Dosage and Administration.)

Common Adverse Effects

Elevated aminotransferases (ALT, AST),¹ ⁴ ⁵ ¹³ ¹⁷ ¹⁹ lipid abnormalities (e.g., decreased HDL cholesterol concentrations).¹ ⁴ ⁵ ¹³ ¹⁹

Interactions for Oxandrolone

Specific Drugs and Laboratory Tests

Drug or Test	Interaction	Comments
Anticoagulants, oral	May potentiate action of oral anticoagulants and decrease anticoagulant requirements¹ ⁴ ²² ²⁴ ²⁶ ³² Increases AUC and half-life of warfarin; minor bleeding reported;¹ ⁴ 80-85% decrease in warfarin dosage (from a mean of 6.13 mg daily to a mean of 1.13 mg daily) were needed to maintain target INR of 1.5 in one study¹ ⁴ ³²	Monitor PT or INR when oxandrolone therapy is initiated or discontinued in patients receiving oral anticoagulants and adjust anticoagulant dosage as needed¹ ⁴ ³² Initial anticoagulant dosage may be substantially lower in patients receiving oxandrolone³² Monitor for signs and symptoms of occult bleeding¹ ⁴
Antidiabetic agents, oral (sulfonylureas)	Possible inhibition of sulfonylurea metabolism¹ ⁴ ³²	Use concomitantly with care⁶
Corticotropin (ACTH) and corticosteroids	May exacerbate edema¹ ⁴	Consider possibility of interaction before use¹³
Tests for thyroid function	Possible decreased thyroxine-binding globulin concentrations, resulting in decreased total serum thyroxine (T₄) concentrations and increased resin uptake of triiodothyronine (T₃) and T₄¹ ⁴ ¹⁶ Free thyroid hormone concentrations remain unchanged¹ ⁴ May decrease protein-bound iodine (PBI) concentrations and radioactive iodine uptake¹ ⁴

Oxandrolone Pharmacokinetics

Absorption

Bioavailability

Well absorbed after oral administration, with peak serum concentrations attained in approximately 1 hour.⁵ ¹³

Distribution

Plasma Protein Binding

95%.⁵ ¹³

Elimination

Metabolism

Partially metabolized via sulfation to 17-epioxandrolone; other metabolites also identified.⁵ ¹³ ¹⁴ ²⁵ ²⁷ ²⁸

Elimination Route

Excreted principally in urine as unchanged and unconjugated oxandrolone (28%).⁵ ²⁵ ²⁷

Half-life

Biphasic; distribution half-life is 30 minutes and elimination half-life is approximately 10.4 hours in adults.¹ ⁵ ²⁵

Special Populations

In geriatric individuals, elimination half-life is 13.3 hours.¹

Stability

Storage

Oral

Tablets

20–25°C.⁴

ActionsActions

Produces marked anabolic activity and relatively few androgenic effects.⁵ ⁶ ⁷ ¹³ ¹⁴ ²²

Produces retention of nitrogen,⁵ ⁷ ¹³ ¹⁷ ²² increases protein anabolism and amino acid utilization, and decreases urinary calcium concentrations.² ⁵ ¹³ ¹⁶ ¹⁸ ²³

Increases lean body mass, body cell mass, and muscle strength.⁷ ⁹ ¹⁶ ¹⁷ ¹⁸ ¹⁹ ²⁰ ²²

Increases bone mineral density and content.⁵ ¹³ ¹⁶ ²²

Inhibits protein catabolism induced by corticosteroids.⁵ ⁶ ⁸ ¹⁷ ²²

Androgens stimulate production of erythrocytes, apparently by enhancing production of erythropoietin.²² (See Hematologic Effects under Cautions.)

Inhibits release of endogenous testosterone via feedback inhibition of pituitary luteinizing hormone (LH).¹ ⁴ ⁷ ⁸ ¹⁰ ¹⁹ ²² ³²

Large doses of androgens may suppress spermatogenesis.¹ ⁴ ⁶ ⁷ ⁸ ⁹ ²²

Advice to Patients

Risk of virilization in females.¹ ² ⁴ ⁶ Advise female patients to contact their clinician if they notice hoarseness, acne, menstrual changes, baldness, genital changes, or growth of facial hair.¹ ² ⁴

Risk of priapism; importance of males informing clinicians if too frequent or persistent penile erections occur.¹ ⁴

Advise male patients to contact their clinician if they notice new or worsening acne.¹ ⁴

Importance of periodic assessments to determine rate of bone maturation in pediatric patients.¹ ⁴

Importance of informing clinician if nausea, vomiting, changes in skin color, or ankle swelling occurs.¹ ⁴

Risk of potential liver toxicity and/or lipid abnormalities (e.g., increased LDL-cholesterol concentrations and decreased HDL-cholesterol concentrations.¹ ⁴ Importance of regular laboratory monitoring of liver function and cholesterol concentrations.¹ ⁴

Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.¹ ⁴

Importance of informing clinician of existing or contemplated concomitant therapy, including prescription (e.g., warfarin, antidiabetic medications) and OTC drugs and herbal supplements, as well as any concomitant illnesses.¹ ⁴

Importance of informing patients of other important precautionary information.¹ ⁴ (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Oxandrolone is subject to control under the Federal Controlled Substances Act of 1970, as amended by the Anabolic Steroids Control Act of 1990 and 2004, as a schedule III (C-III) drug.¹¹

Oxandrolone
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Tablets	2.5 mg	Oxandrin ( C-III; scored)	Savient
			Oxandrolone Tablets ( C-III; scored)
		10 mg	Oxandrin ( C-III)	Savient
			Oxandrolone Tablets ( C-III)

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Oxandrin 10MG Tablets (SAVIENT PHARMACEUTICALS INC.): 30/$822.73 or 60/$1621.34

Oxandrin 2.5MG Tablets (SAVIENT PHARMACEUTICALS INC.): 30/$249.24 or 90/$725.97

Oxandrolone 10MG Tablets (SANDOZ): 30/$535.96 or 90/$1577.85

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Savient Pharmaceuticals. Oxandrin (oxandrolone) tablets prescribing information. East Brunswick, NJ; 2006 Jan.

2. AHFS consumer medication information. Oxandrolone. Bethesda, MD: American Society of Health-System Pharmacists; 2004 Oct 1. Available from website. Accessed 2008 Mar 7.

3. Food and Drug Administration. List of orphan designations and approvals. Rockville, MD; 2007 Oct 4. From FDA website. Accessed 2008 Mar 7.

4. Par Pharmaceutical Companies. Oxandrolone tablets prescribing information. Spring Valley, NY; 2007 Mar 3.

5. Orr R, Singh MF. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs. 2004; 64:725-50. [PubMed 15025546]

6. Kam PCA, Yarrow M. Anabolic steroid abuse: physiological and anaesthetic considerations. Anaesthesia. 2005; 60:685-92. [PubMed 15960720]

7. American College of Sports Medicine. Position stand on the use of anabolic-androgenic steroids in sports. Med Sci Sports Exerc. 1987; 19:534-9. [PubMed 3316907]

8. Committee on Sports Medicine and Fitness, American Academy of Pediatrics. Adolescents and anabolic steroids: a subject review. Pediatrics. 1997; 99:904-8. [PubMed 9190555]

9. Council on Scientific Affairs, American Medical Association. Medical and nonmedical uses of anabolic-androgenic steroids. JAMA. 1990; 264:2923-7. [IDIS 274793] [PubMed 2232088]

10. Council on Scientific Affairs, American Medical Association. Drug abuse in athletes: anabolic steroids and human growth hormone. JAMA. 1988; 259:1703-5. [IDIS 239600] [PubMed 3278150]

11. Drug Enforcement Administration (DEA), Department of Justice. Implementation of the Anabolic Steroid Control Act of 2004. Final rule. [21 CFR Part 1300 and 1308] Fed Regist. 2005; 70:74653-8.

12. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical practice guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. Endocr Pract. 2002; 8:440-56. [PubMed 15260010]

13. Akyurek M, Dunn RM. Oxandrolone. Plast Reconstr Surg. 2006; 118:791-4. [PubMed 16932191]

14. Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996; 42:1001-20.

16. Przkora R, Jeschke MG, Barrow RE et al. Metabolic and hormonal changes in severely burned children receiving long-term oxandrolone treatment. Ann Surg. 2005; 242:384-91. [PubMed 16135924]

17. Jeschke MG, Finnerty CC, Suman OE et al. The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic reponses during the acute phase postburn. Ann Surg. 2007; 246:351-62. [PubMed 17717439]

18. Wolf SE, Thomas SJ, Dasu MR et al. Improved net protein balance, lean mass, and gene expression changes with oxandrolone treatment in the severely burned. Ann Surg. 2003; 237:801-11. [PubMed 12796576]

19. Grunfeld C, Kotler DP, Dobs A et al. Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr. 2006; 41:304-14. [PubMed 16540931]

20. Kravetz JD, Lee C, Dieterich DT. Oxandrolone use in Crohn’s disease. Am J Gastroenterol. 1997; 92:2330-1. Letter [PubMed 9399787]

21. Dickerman RD, Joseph AM, Bennett MT. Corticosteroid-induced myopathy in spinal cord injury patients: a role for anticatabolic agents? Spinal Cord. 2006; 44:263-4. Letter

22. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther. 2001; 23:1355-90. [PubMed 11589254]

23. Riggs BL, Jowsey J, Kelly PJ et al. Studies on pathogenesis and treatment in postmenopausal and senile osteoporosis. Clin Endocrinol Metab. 1973; 2:317-32. [PubMed 4373194]

24. Bristol-Myers Squibb. Coumadin (warfarin sodium) tablets crystalline and Coumadin (warfarin sodium) for injection prescribing information. Princeton, NJ; 2007 Aug.

25. Massé R, Bi H, Ayotte C et al. Studies on anabolic steroids II—Gas chromatographic/mass spectrometric characterization of oxandrolone urinary metabolites in man. Biomed Environ Mass Spectrom. 1989; 18:429-38.

26. Koller EA, Wei X, Johnson TE. Oxandrolone steroid use and impaired coagulation. Arch Intern Med. 2006; 166:125. Letter. [PubMed 16401821]

27. Bi H, Massé R. Studies on anabolic steroids—12. Epimerization and degradation of anabolic 17β-sulfate-17α-methyl steroids in human: qualitative and quantitative GC/MS analysis. J Steroid Biochem Molec Biol. 1992; 42:533-46. [PubMed 1616883]

28. Gonzalez FJ, Tukey RH. Drug metabolism. In: Brunton L, Lazo JS, Parker KL, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006:82.

29. August D, Teitelbaum D, Albina J et al. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. Section XI: Specific guidelines for disease—adults. JEPN. 2002; 26:61S-96SA.

30. ICN Pharmaceuticals. Android (methyltestosterone) capsules prescribing information. Costa Mesa, CA; 2001 Sep.

31. Upsher-Smith Laboratories. Androxy (fluoxymesterone) tablets prescribing information. Minneapolis, MN; 2006 May.

32. Savient Pharmaceuticals, East Brunswick, NJ: Personal communication

33. AHFS drug information 2008. McEvoy GK, ed. Corticosteroids general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2008:3088.

34. Alaven Pharmaceutical. Anadrol (oxymetholone) prescribing information. Marietta, GA; 2006 Dec.

More Oxandrolone resources

Oxandrolone Side Effects (in more detail)
Oxandrolone Dosage
Oxandrolone Use in Pregnancy & Breastfeeding
Drug Images
Oxandrolone Drug Interactions
Oxandrolone Support Group
0 Reviews for Oxandrolone - Add your own review/rating

Oxandrolone Prescribing Information (FDA)

Oxandrolone MedFacts Consumer Leaflet (Wolters Kluwer)

Oxandrolone Professional Patient Advice (Wolters Kluwer)

oxandrolone Concise Consumer Information (Cerner Multum)

Oxandrin Prescribing Information (FDA)

Compare Oxandrolone with other medications

Alcoholic Liver Damage
Turner's Syndrome
Weight Loss

Friday, 1 July 2011

Egoderm Ointment

Egoderm Ointment may be available in the countries listed below.

Ingredient matches for Egoderm Ointment

Ichthammol

Ichthammol is reported as an ingredient of Egoderm Ointment in the following countries:

New Zealand

Zinc Oxide

Zinc Oxide is reported as an ingredient of Egoderm Ointment in the following countries:

New Zealand

International Drug Name Search